CASI Pharmaceuticals, Inc.
CASI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $43,412 | $95,659 | $24,429 | $108,884 |
| - Cash | $13,468 | $17,083 | $47,112 | $38,704 |
| + Debt | $22,141 | $21,239 | $1,344 | $4,332 |
| Enterprise Value | $52,085 | $99,815 | -$21,339 | $74,512 |
| Revenue | $28,537 | $33,879 | $43,107 | $30,168 |
| % Growth | -15.8% | -21.4% | 42.9% | – |
| Gross Profit | $11,146 | $20,052 | $27,280 | $17,611 |
| % Margin | 39.1% | 59.2% | 63.3% | 58.4% |
| EBITDA | -$34,867 | -$21,539 | -$24,069 | -$33,402 |
| % Margin | -122.2% | -63.6% | -55.8% | -110.7% |
| Net Income | -$39,258 | -$26,938 | -$41,014 | -$36,654 |
| % Margin | -137.6% | -79.5% | -95.1% | -121.5% |
| EPS Diluted | -2.56 | -2.02 | -3.01 | -2.69 |
| % Growth | -26.7% | 32.9% | -11.9% | – |
| Operating Cash Flow | -$29,224 | -$19,967 | -$21,088 | -$26,842 |
| Capital Expenditures | -$240 | -$2,241 | -$5,612 | -$15,500 |
| Free Cash Flow | -$29,464 | -$22,208 | -$26,700 | -$42,342 |